In re Nexium (Esomeprazole) Antitrust Litigation, No. 1:12-md-02409-WGY (D. Mass.)


In Nexium, Faruqi & Faruqi, who filed the very first complaint on behalf of direct purchasers, represents a certified class of direct purchasers of the prescription drug Nexium.  The direct purchaser class alleges that in the brand manufacturer, AstraZeneca, entered into illegal reverse-payment agreements with certain generic manufacturers (namely Ranbaxy, Teva, and Dr. Reddy’s) to delay the entry of more affordable generic Nexium.  The class also alleges that AstraZeneca brokered a single conspiracy among all 3 generic manufacturers to achieve that same illegal delay in generic competition.  The case has proceeded through dispositive motions practice and is scheduled for trial in October of 2014.  Peter Kohn is on the trial team for this case.

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.

Details

Filed on 08/27/2012

Office

1617 JFK Boulevard, Suite 1550

19103 Philadelphia, Pennsylvania

Phone (215) 277-5770

Fax (215) 277-5771

Counsel

Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771

Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania